BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, March 15, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
April 14, 1999
View Archived Issues
BioStratum completes equity financing; updates research goals
Read More
Amarillo begins phase III trial of interferon alfa for Sjogren's syndrome
Read More
Results from phase III study of appendicitis diagnostic reported
Read More
Isis and Elan sign antisense agreement
Read More
Spotlight on MMP inhibitors in development for cancer
Read More
Peptidomimetic inhibitors of cellular Ras protein processing developed at Merck
Read More
Epicyte awarded SBIR and DARPA grants
Read More
Roche describes preparation and use of cell adhesion inhibitors for chronic inflammatory disorders
Read More
Serotonergic agents for depression under study at BASF
Read More
Production method and structure of all-trans-retinol metabolite disclosed by WARF
Read More
Orquest's bone substitute product approved in E.C.
Read More
HMR continues to focus R&D resources in the area of Na+/H+ exchange inhibitors
Read More
Novel macrolide antitumor agent in early clinical trials at Wyeth-Ayerst
Read More
Preclinical studies indicate potential of MMP inhibitor in brain and prostate cancers
Read More
4'-Thio-ara-C selected as potential clinical candidate at Southern Research Institute
Read More
AEterna presents evidence of clinical efficacy of lead MMP inhibitor at AACR meeting
Read More
News from AACR: orally active cemadotin analogue from BASF heads for clinic
Read More
Angiogenic molecules emerge as an important therapeutic target in cancer
Read More
Anti-VEGF aptamer is a potent inhibitor of tumor angiogenesis
Read More
Controlled-release formulation of paclitaxel endowed with superior in vivo antitumor activity
Read More
Once-weekly administration of topoisomerase II inhibitor is associated with reduced toxicity
Read More
Orally active MDR-reversing agent in phase I presented at AACR by Janssen
Read More
NIH investigates next-generation cancer immunotherapeutic
Read More
CL-387785: covalent, irreversible inhibitor of EGF and related receptor tyrosine kinases
Read More
Colazide receives pricing approval in Sweden
Read More
Farnesyltransferase inhibitors especially effective in combination with other chemotherapeutic drugs
Read More
Substituted purines and pyrimidines as inhibitors of cyclin-dependent kinases
Read More
E.U.-wide approval obtained for Regranex
Read More
